Effect of HFR-SUPRA in the Treatment of Multiple Myeloma-related Acute Kidney Injury

• Status: Not yet recruiting
• Trial end date: 2032-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In patients with multiple myeloma-related acute kidney injury, compare the renal outcome of chemotherapy combined with HFR-SUPRA to chemotherapy combined with hemodialysis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital
• Collaborator: Bellco Hoxen Medical (Shanghai) Co., Ltd

Criteria

Inclusion Criteria:

• 18 to 80 years old

• new onset of multiple myeloma

• acute kidney injury with eGFR < 15 ml/min/1.73m2 and need hemodialysis

• biopsy-proven cast nephropathy or clinical diagnosis of cast nephropathy based on exclusion of other causes of acute kidney injury including post-renal obstruction, hypercalcaemia, amyloidosis, light-chain deposition disease, contrast media and drug nephropathy

• serum light chain > 500 mg/L

Exclusion Criteria:

• chronic kidney disease stage 3 to 5 (eGFR< 60 ml/min/1.73m2 for at least 3 months)

• haemodynamics unstability

• active bleeding

• cardiovascular and cerebrovascular events in the last month

• other malignant tumor

• conditions not suitable to participate in the study, such as bad compliance